AstraZeneia's Symbicort reduces asthma attacks

's novel START trial of Symbic Turbuhaler (Budined/Formotro) showed a lower rate of asthma attacks in people with mild asthma than in general therapies.The results, published in the New England Journal of Medicine, compared Symbicort Turbuhaler with two commonly used treatments for mild asthma and reflected real-world practice.In real-world practice, patients typically use short-acting beta-2-excited agents (SABA) relievers to cope with symptoms or use SABA relievers for daily low-dose inhaled corticosteroid (ICS) maintenance therapy.In this trial, patients with mild asthma were randomly given salbutamol (a SABA reliever) as needed, or budineide (ICS maintenance therapy) and salbutamol as needed, or Symbicort Turbuhaler as an anti-inflammatory reliever.The results showed a 51 per cent reduction in the rate of acute asthma attacks per year compared to salbutamol, and although the average steroid dose with Symbicort Turbuhaler was reduced by 52 per cent, there was no difference between the use of Symbicol Turbuhaler and the rate of deterioration of budenad gaddamine, which was maintained twice daily.“ There are an estimated 176 million asthma attacks worldwide each year, and all asthma sufferers are at risk of severe seizures regardless of the severity of the disease, explains Alex de Giorgio-Miller, vice president of respiratory therapy for global medical services.he continued, "Compared to the most commonly used asthma relievers, the new START trial demonstrates the effectiveness of Symbicort as an anti-inflammatory reliever that reduces the risk of asthma attacks in people with mild illness." In a trial that reflected real-world practice, the data reinforced the evidence in the SYGMA trial and established clinical characteristics of Symbicort in moderate to severe diseases. TheSTART trial was conducted by the New Zealand Institute of Medicine, funded by AstraZeneta's research and funded by the core body of the New Zealand Health Research Council. (Compiled by this web)